成年女性尿失禁就医意向及生活质量研究进展

尿失禁作为重要的医疗卫生问题,其导致的经济损失已受到广泛关注。在我国,多达3.49亿成年女性受到尿失禁的困扰,但很少有女性主动求医。对疾病的认知、症状的严重程度及人口社会学因素与女性就医意向密切相关,评价尿失禁生活质量以促进女性就医、改善其生活质量是迫切需要解决的问题。综述近年来成年女性尿失禁就医意向及生活质量的相关研究,为医疗工作提供参考。     

非编码RNAs对甲状腺乳头状癌的分子调控机制研究进展

甲状腺乳头状癌是甲状腺癌中最常见的亚型。虽然通过甲状腺切除术、微波消融术、放射性碘和激素替代治疗甲状腺乳头状癌能达到一定治疗效果,但仍然无法有效地降低其发病率、死亡率和复发率。因此,寻求甲状腺乳头状癌发生发展的分子机制,为甲状腺乳头状癌患者提供有效的早期诊断、精确的治疗以及较好的长期预后显得尤为重要。本文通过总结非编码RNAs及其相关信号通路对甲状腺乳头状癌发生发展的分子调控机制,以期为甲状腺乳头状癌生物标志物的进一步研究提供新思路。     

细胞因子诱导杀伤细胞过继免疫联合化疗治疗食管癌的Meta分析

目的:评价细胞因子诱导杀伤细胞(CIK)过继免疫联合化疗治疗食管癌的临床疗效.方法:计算机检索CNKI、CBM、VIP、WanFang、Cochrane Library、PubMed、Embase、Web of Science,收集所有CIK细胞过继免疫联合化疗治疗食管癌的相关研究,检索时限为建库至2020年02月20...     

代谢综合征与胃癌发病风险的Meta分析

目的 采用Meta法评价代谢综合征(MetS)与胃癌(GC)发病风险的关系.方法 计算机检索CNKI、WanFang Data、VIP、CBM、Web of Science、The Cochrane Library及PubMed数据库,搜集国内外关于MetS与GC相关的病例—对照研究,检索时限均为建库至2020年6月....     

GCLC及GCLM在胃癌组织中的表达及其临床意义

目的:评估谷氨酸-半胱氨酸连接酶催化亚基(glutamate cysteine ligase catalytic subunit, GCLC)及其修饰亚基(glutamate cysteine ligase modifier subunit, GCLM)在胃癌中的表达水平及其与患者临床病理特征的相关性。方法:采用免疫组织化学法检测GCLC和GCLM在胃癌组织中的蛋白表达水平。结果:胃癌组织中GCLC和GCLM的表达均显著高于癌旁组织。GCLC和GCLM染色阳性的胃癌分别为89.8%和79.7%,明显高于邻近正常组织(分别为11.9%和3.4%)。胃癌中GCLC和GCLM的表达与患者的肿瘤大小、分化程度及临床分期相关(P<0.05)。我们通过Spearman相关性分析统计发现GCLC和GCLM表达存在相关性(r=0.526 6,P<0.000 1)。结论：GCLC和GCLM在胃癌中的高表达可能与肿瘤发生发展有关并为胃癌诊断及治疗提供理论依据。     

内脏型肥胖对右半结肠癌术后早期并发症的影响

目的:探究内脏型肥胖对右半结肠癌根治术后早期并发症的影响。方法:回顾性分析2020年10月至2022年10月在甘肃省人民医院肛肠科接受右半结肠癌根治性手术治疗患者的临床病理资料。依据患者术前1个月内的腹部CT资料,估计内脏脂肪面积（visceral fat area,VFA）,将VFA≥100 cm2归为VFA-H组,VFA＜100 cm2归为VFA-L组。比较两组患者的临床病理特征和术后早期并发症情况。采用单因素及多因素 Logistic回归模型,分析影响右半结肠癌术后早期并发症发生的危险因素。结果:共纳入112例右半结肠癌患者,其中VFA-H组共49例,VFA-L组共63例。两组患者性别、年龄、肿瘤大小、T分期、分化程度、白蛋白比较差异无统计学意义（P＞0.05）;TNM分期、BMI、ASA分级比较差异有统计学意义（P＜0.05）。两组患者术中和术后情况相比,VFA-H组术中出血量更多,差异有统计学意义（P＜0.05）;手术时间、术后首次通气时间、术后首次排便时间、术后住院时间比较差异无统计学意义（P＞0.05）。单因素分析结果显示,手术时间＞180 min和VFA≥100 cm2是右半结肠癌术后早期并发症发生的危险因素（P＜0.05）;多因素分析结果显示,VFA≥100 cm2是右半结肠癌术后早期并发症发生的独立危险因素（P＜0.05）。结论:VFA≥100 cm2是右半结肠癌术后早期并发症发生的独立危险因素。     

达雷妥尤单抗在血液系统疾病治疗中的应用及其耐药机制的研究进展

达雷妥尤单抗（Daratumumab,Dara）是第一代抗CD38单克隆抗体,具有免疫调节、抗体依赖性细胞介导的细胞毒性作用、抗体依赖性细胞吞噬作用、补体依赖性细胞毒性作用。近年来关于抗CD38单克隆抗体在血液系统疾病中的研究及应用较多,本文旨在综述近年来达雷妥尤单抗在复发难治性多发性骨髓瘤、新诊断的多发性骨髓瘤、系统性淀粉样变性、具有肾脏意义的单克隆丙种球蛋白病等血液系统疾病治疗中的应用及其耐药机制的研究进展。     

Glutamate-cysteine ligase catalytic and its modifier function as novel immunotargets in gastric adenocarcinoma

ObjectivesTo determine the expression and function of glutamate-cysteine ligase catalytic (GCLC) and glutamate-cysteine ligase catalytic modifier (GCLM) in gastric adenocarcinoma.MethodsBioinformatics was used to analyze the expression of GCLC and GCLM. We download and analyzed the expression of gastric adenocarcinoma patients from TCGA database. Moreover, the method of immunochemistry was used to verify the expression of GCLC and GCLM in gastric adenocarcinoma.ResultsAt first, the expression of GCLC and GCLM in gastric adenocarcinoma tissues were both significantly higher compared with normal tissues analyzed via TCGA database. Then, gastric adenocarcinoma tissues were collected and performed with immunochemistry. The gastric adenocarcinoma with positive staining for GCLC and GCLM was 77% and 80%, respectively, which was significantly higher compared with adjacent normal tissues (9% and 11%, respectively).ConclusionsThe disordered expression of GCLC and GCLM in gastric adenocarcinoma suggested that these factors may induce tumorigenesis and may be a novel target for diagnosis and treatment of gastric adenocarcinoma.     

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

One hundred and five patients with inoperable non-small cell lung cancer were included in a randomized trial comparing the activity of vindesine as a single agent with the combination of vindesine and cisplatin. All patients were previously untreated and the majority (70%) had squamous carcinoma. The overall partial response rates in 88 evaluable patients were 7% for vindesine alone and 33% for the combined regime. There were no complete responders in either arm. The median survival of patients treated with vindesine and cisplatin was 11 months, compared with 4 months in those treated with vindesine alone (P = 0.008). Patients showing a partial or complete response to vindesine and cisplatin survived a median duration of 13 months, compared with 7 months for non-responders (P = 0.03). This survival benefit associated with the combination was particularly apparent for patients with ECOG performance status 0 or 1 (median survival > 18 months and 13 months respectively), locoregional disease (median survival 14 months) and squamous cell histology (median survival 13 months). Myelo-suppression was greater with the combination but was not a major treatment problem. Neurotoxicity, which was frequently dose-limiting, was of similar severity in both treatment groups. The results indicate that the combination of vindesine and cisplatin is superior to vindesine alone for remission induction in non-small cell lung cancer and confers a significant survival advantage compared with vindesine alone in patients with favourable prognostic factors.